Ruxolitinib for Polycythemia Vera Intolerant or Resistant to Hydroxyurea

Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, introduce themselves and provide insights on the prevalence of hydroxyurea resistance or intolerance in patients with polycythemia vera (PV) and how it impacts treatment decisions and costs.

Gabriela Hobbs, MD, provides an overview of the role of ruxolitinib in treating patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

Experts on polycythemia vera provide a comprehensive overview of the objectives and study design of the MAJIC-PV clinical trial, highlighting key endpoints.

Gabriela Hobbs, MD, describes characteristics of the patient population included in the MAJIC-PV study, and analyzes best available therapies received in the comparator arm.

A comprehensive overview of key findings from the MAJIC-PV trial investigating ruxolitinib in patients with polycythemia vera, highlighting efficacy and symptom improvement.

Following a review of the safety analysis of MAJIC-PV, the panel discusses the main limitations and key takeaways from the study.

Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP, close the discussion with key takeaways for payers to consider related to ruxolitinib and insights on future research.